A recent study concluded that universal molecular testing in stage 4 non-small cell lung cancer is a critical first step in determining the best course of treatment; but adoption of next-generation sequencing (NGS) has been slow. Here, Thermo Fisher Scientific’s Dr Luca Quagliata discusses the issues around widespread introduction of NGS and how oncologists and pathologists can use it to improve outcomes for cancer patients.
Genomic sequencing can have a profound impact on patient outcomes and can hold the key to unlocking a world of more precise, tailored care based on a cancer’s unique genomic profile.
A recent study published in JCO Oncology Practice authored by researchers at MGH, the Sarah Cannon Research Institute, The University of Toledo, UPMB Hillman Cancer Center, Integra Connect and Thermo Fisher Scientific further reinforces the importance of genomic sequencing for cancer patients prior to the start of treatment. More specifically, the study explored real-world data of patients with non-small cell lung cancer (NSCLC) and concluded that universal molecular testing in stage 4 NSCLC is a critical first step in determining the best course of treatment for patients. The research further points out that prescribing a one-size-fits-all treatment before next-generation sequencing (NGS) results are available may compromise patient outcomes.
However, in-house adoption of NGS has been slow and not enough patients are reaping the benefits of genomic sequencing. According to a 2021 US study, less than half of patients who qualify end up getting their tumours sequenced. With patients more likely than ever to be diagnosed with late-stage cancers, there is no time to waste in identifying an optimal treatment.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.